Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...